FX.co ★ Ipsen Q3 Sales Increase; Lifts FY24 Outlook - Quick Facts

French specialty-care biopharmaceutical company Ipsen (IPSEY) announced on Wednesday an 8.3% increase in total sales for the third quarter, reaching 836.6 million euros compared to 772.4 million euros in the previous year. When accounting for constant currency, sales exhibited an 8.6% growth.

The oncology segment achieved sales of 604 million euros, a 5.1% rise from the previous year. Neuroscience sales experienced a 10.4% increase to 181.9 million euros, while sales in the Rare Disease sector surged by 53.1% to 50.8 million euros.

Looking forward, Ipsen now anticipates a total sales growth exceeding 8.0% at constant exchange rates (CER), revising its earlier projection of growth above 7.0% at CER. The core operating margin is now expected to surpass 31.0% of total sales, an improvement from the previous guidance of over 30%.

Year-to-date, total sales have grown by 8.1% as reported, with significant contributions from products such as Dysport (abobotulinumtoxinA), Cabometyx (cabozantinib), and Bylvay (odevixibat), among others.